Phase 2 N=60 Efficacy of ClōSYS® Sensitive Fluoride Toothpaste and ClōSYS® Sensitive Rinse Regimen on MGI, PI and BOP
Gingivitis · Periodontitis
Primary: Changes in Modified Gingival Index (MGI) — 8.5; 1.5 score on a scale — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=896 An Implementation Strategy for the Adoption of an Evidence-Based Guideline for Pit-and-Fissure Sealants
Pit-and-Fissure Sealants
Primary: Change in Providers' Rates of Placing or Treatment Planning Sealants for Occlusal NCCLs — 137; 95 Teeth — p=0.18
N/A N=823 Weight Loss and Exercise for Communities With Arthritis in North Carolina
Osteoarthritis
Primary: Knee Pain — 5.0; 5.5 score on a scale
Phase 3 N=98 Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy
Kidney Stones
Primary: Number of Participants With Infectious Complications — 6; 7; 6; 8 Participants
Phase 2 N=8 A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Nocturnal Hemoglobinuria
Primary: Change From Baseline in LDH Level at Week 25 — -683.29 U/L
Phase 3 N=342 Treatment of COVID-19 Patients With Anti-interleukin Drugs
COVID-19
Primary: Time to Clinical Improvement — 12; 12; 11; 12 days
Phase 3 N=221 An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva.
Fibrodysplasia Ossificans Progressiva
Primary: Annualized New Heterotopic Ossification (HO) — 9427.1; 23720.2 cubic millimeters (mm^3)
Phase 2 N=21 A Safety Study of BBI-4000 Gel in Pediatric Patients With Axillary Hyperhidrosis
Primary Axillary Hyperhidrosis
Primary: The Number of Participants With Treatment Emergent Adverse Events (All TEAEs). — 5; 5; 0 Participants
Phase 4 N=88 The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence
Mixed Urinary Incontinence · Stress Urinary Incontinence · Urgency Incontinence
Primary: Number of Participants With Self-reported Mixed Urinary Incontinence Symptoms — 31; 34 Participants
N/A N=28 Wound Dressings for Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Dermatology Life Quality Index (DLQI) Scores — 15.5; 12.5 score on a scale
N/A N=18,353 VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL
Depression · Depressive Symptoms · Mood
Primary: Number of Participants With a Depression Event — 609; 625; 651; 583 Participants — p=0.62
Phase 4 N=20 Parcopa Versus Carbidopa-levodopa in a Single Dose Cross-over Comparison Study
Parkinson's Disease
Primary: Measurement of Time in Minutes From When a Patient Was in a Clinical "Off" State, Took Their Medication and Went Into a Clinical "on" State — 23.9; 28.5 minutes
Phase 4 N=427 A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
Asthma
Primary: Number of Participants Achieving Well-Controlled Asthma or Reaching Clinically Important Improvement in Asthma Control — 112; 134 Participants
Phase 2 N=80 Anti-Cytokine Therapy for Hemodialysis InflammatION
End-Stage Renal Disease
Primary: Safety and Tolerability of Anakinra, for Patients Receiving Maintenance Hemodialysis — 2.71; 2.74 events per patient-year
N/A N=200 Intervention to Improve Developmental and Health Outcomes for Female Adolescents
Independent Child Migration
Primary: Intention to Migrate — 1.72; 1.15; 1.42; 1.28 Score on a scale — p=0.05